Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Boyd, Anders ^a   Meynard, Jean Luc ^b,c   Morand Joubert, Laurence ^d   Michon, Adrien ^d   Boccara, Franck ^b,d,e   Bastard, Jean Philippe ^b,f   Samri, Assia ^b,g   Haddour, Nabila ^b,d   Mallat, Ziad ^h,i   Capeau, Jacqueline ^b,f   Desvarieux, Moïse ^j,k   Girard, Pierre Marie ^a,b,c  

^a INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^f HÔPITAL TENON   (France)

^g INSERM   (France)

^h PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j Mailman School of Public Health ^*  (United States)

^k EHESP SCHOOL OF PUBLIC HEALTH   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMYLOID A PROTEIN; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 27; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PADGEM PROTEIN; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ASSAY; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN RESISTANCE; LIMIT OF QUANTITATION; LINEAR REGRESSION ANALYSIS; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VIREMIA; VIRUS REPLICATION; ATHEROSCLEROSIS; BLOOD; COMMON CAROTID ARTERY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PATHOLOGY; PATHOPHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTI-RETROVIRAL AGENTS; ATHEROSCLEROSIS; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIREMIA;

EID: 84912084734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113876     Document Type: Article

References (24)

1. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3879-3884. doi:10.1073/pnas.0800050105.
2. Hatano H, Delwart EL, Norris PJ, Lee T-H, Neilands TB, et al. (2010) Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24: 2535-2539. doi:10.1097/QAD.0b013e32833dba03.
3. Chun T-W, Murray D, Justement JS, Hallahan CW, Moir S, et al. (2011) Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 204: 135-138. doi:10.1093/infdis/jir208.
4. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, et al. (2012) Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 60: 473-482. doi:10.1097/QAI.0b013e3182567a57.
5. Bastard J-P, Soulié C, Fellahi S, Haïm-Boukobza S, Simon A, et al. (2012) Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 17: 915-919. doi:10.3851/IMP2093.
6. Eastburn A, Scherzer R, Zolopa AR, Benson C, Tracy R, et al. (2011) Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 6: e26320. doi:10.1371/journal.pone.0026320.
7. Desvarieux M, Boccara F, Meynard J-L, Bastard J-P, Mallat Z, et al. (2013) Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapy. AIDS 27: 2603-2614. doi:10.1097/QAD.0b013e3283634819.
8. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, et al. (2005) Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 111: 576-582. doi:10.1161/01.CIR.0000154582.37101.15.
9. Koenker R, Bassett G (1982) Robust Tests for Heteroscedasticity Based on Regression Quantiles. Econometrica 50: 43-61.
10. Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, et al. (2010) Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 17: 491-501. doi:10.1097/HJR.0b013e328336a150.
11. Baker JV, Henry WK, Patel P, Bush TJ, Conley LJ, et al. (2011) Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 53: 826-835. doi:10.1093/cid/cir497.
12. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, et al. (2009) Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23: 1059-1067. doi:10.1097/QAD.0b013e32832b514b.
13. Pereyra F, Lo J, Triant VA, Wei J, Buzon MJ, et al. (2012) Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 26: 2409-2412. doi:10.1097/QAD.0b013e32835a9950.
14. Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, et al. (2012) Mannheim carotid intimamedia thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 34: 290-296. doi:10.1159/000343145.
15. Ando F, Takekuma K, Niino N, Shimokata H (2000) Ultrasonic evaluation of common carotid intimamedia thickness (IMT)-influence of local plaque on the relationship between IMT and age. J Epidemiol 10: S10-17.
16. Mercié P, Thiébaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives MC, et al. (2005) Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 6: 380-387. doi:10.1111/j.1468-1293.2005.00324.x.
17. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA (2011) Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 214: 468-473. doi:10.1016/j.atherosclerosis.2010.11.013.
18. Ross AC, Rizk N, O9Riordan MA, Dogra V, El-Bejjani D, et al. (2009) Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 49: 1119-1127. doi:10.1086/605578.
19. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, et al. (2003) Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 77: 11212-11219.
20. Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, et al. (2014) Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med 15: 431-441. doi:10.1111/hiv.12128.
21. Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, et al. (2013) Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 208: 892-897. doi:10.1093/infdis/jit280.
22. Gupta SK, Mi D, Moe SM, Dubé MP, Liu Z (2013) Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr 64: 279-283.
23. Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, et al. (2012) The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 26: 1885-1894. doi:10.1097/QAD.0b013e3283584521.
24. Lam YMP, McBride KL, Amin J, Cordery DV, Kelleher AD, et al. (2012) Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. PLoS One 7: e31990. doi:10.1371/journal.pone.0031990.